CATX

Perspective Therapeutics, Inc.
$2.94
-0.06 (-1.84%)
Mkt Cap 225.96M
Volume 685,519
52W Range 1.96-6.16
Sector Healthcare
Beta 1.75
EPS (TTM) -26.44
P/E Ratio -1.96
Revenue (TTM) 618,000
Rev Growth (5Y) -35.3%
EPS Growth (5Y) N/A

Company Description

Track Record

Showing latest 4 periods • Swipe for more
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Revenue 0 1.45M 1.43M 7.10M 10.79M 10.05M 9.68M 7.31M 5.92M 4.76M 4.77M 4.61M
Net Income (103.12M) (79.28M) (46.51M) (14.67M) (7.15M) (3.19M) (3.27M) (4.85M) (6.70M) (6.16M) (4.71M) (3.68M)
EPS -1.40 -1.23 -0.85 -0.27 -0.13 -0.06 -0.05 -0.07 -0.12 -0.11 -0.09 -0.07
Free Cash Flow (95.23M) (72.71M) (37.98M) (12.47M) (7.98M) (3.22M) (3.91M) (5.49M) (6.05M) (6.26M) (4.38M) (3.67M)
FCF / Share -1.29 -1.13 -0.69 -0.23 -0.15 -0.06 -0.06 -0.08 -0.11 -0.11 -0.08 -0.07
Operating CF (82.48M) (18.29M) (36.91M) (12.17M) (7.71M) (2.84M) (3.64M) (5.05M) (5.71M) (5.71M) (3.88M) (3.52M)
Total Assets 266.97M 341.10M 97.89M 58.09M 67.25M 15.51M 8.70M 9.42M 7.46M 12.27M 18.10M 23.00M
Total Debt 3.25M 4.06M 2.55M 524,000 652,000 897,000 1.00M 0 0 0 0 0
Cash & Equiv 30.63M 61.58M 9.24M 20.99M 60.35M 9.59M 2.39M 5.33M 2.60M 5.93M 10.14M 5.23M
Book Value 207.03M 290.67M 75.18M 54.64M 64.39M 12.77M 5.72M 7.68M 5.03M 10.60M 16.40M 20.78M
Return on Equity -0.50 -0.27 -0.62 -0.27 -0.11 -0.25 -0.57 -0.63 -1.33 -0.58 -0.29 -0.18
CATX News
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026
Jul 17, 2026 08:22 AM · globenewswire.com
Is Perspective Therapeutics, Inc. (CATX) Stock Outpacing Its Medical Peers This Year?
Jul 16, 2026 06:40 AM · zacks.com
Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K.
Jul 08, 2026 02:30 AM · globenewswire.com
Perspective Therapeutics doses first brain tumor patient in expanded radiopharmaceutical trial
Jun 03, 2026 10:08 AM · proactiveinvestors.com
Perspective Therapeutics doses first brain tumor patient in expanded radiopharmaceutical trial
Jun 03, 2026 06:06 AM · proactiveinvestors.com
Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study
Jun 03, 2026 02:30 AM · globenewswire.com
Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma
May 21, 2026 01:51 PM · globenewswire.com
Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies
May 18, 2026 02:30 AM · globenewswire.com
Perspective Therapeutics, Inc. (CATX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
May 13, 2026 04:00 PM · seekingalpha.com
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results
May 11, 2026 12:07 PM · globenewswire.com